

Alexandre de Sousa Calaça Pereira Baptista

Address: Rua das Musas lote 03.07.03. 3ºb 1900-113 Lisbon

Phone: 00351 91 212 71 28, email alexcalaca@hotmail.com

Profile

I am a motivated, problem-solving person with Global and National experience and formal education in Health Economics and Epidemiology.

Line management experience during my career and Mentor of University of York students in 2014.

Work Experience

Researcher

UEPID- Faculty of Medicine of Lisbon

Lisbon, November 2014-

- Project management and Business Development in the field of consultancy to the pharmaceutical industry in HEOR
- Organization and presentation of lessons and courses in the fields of health economics and epidemiology

Project Manager of Health Economic and Epidemiological studies

Centre for Health Evaluation & Research (CEFAR), National Association of Pharmacies

Lisbon, February 2013- August 2014

- Project management and Business Development in the field of consultancy to the industry in the health economic and epidemiological areas specifically with the mission to provide know-how regarding adaptation of Global Value Dossiers to the Portuguese Reality, elaboration of Cost-effectiveness studies and Cost-utility studies and adaptation of Decision Tree and Markov models, Outcomes Research studies and Epidemiological studies
- Monitoring the external environment, to assess any risks due to changes in prices or legislation

Technical Director

Biotop

A small pharmaceutical company that distributes medical devices and pharmaceutical products in Portugal, Spain, Brazil, Angola and Mozambique. It has its main offices in Estoril, Lisbon, Portugal.

Lisbon, May 2011 – January 2013

Global Health Economist

Solvay Pharmaceuticals HQ / Global Product Strategic Marketing Department

Hannover-Basel, February 2008 – February 2009

- Member of the Cardiometabolic Fenofranchise team providing health economics expertise and support for the Cardiometabolic Fenofranchise
- Cardiometabolic Fenofranchise was the main business of Solvay Pharmaceuticals

- Member of the Global Launch teams with responsibilities in the design of the Global launch plans in cooperation with the Business Units and its Vice Presidents, Global Regulatory Affairs and Global Pricing teams
- Responsible for the health economic content of the Cardio FenoFranchise Strategic Business Plan
- Provided education to internal stakeholders, like local Market Access and Technical Directors about Health Economics in Global Meetings in Brussels and in Solvay HQ.
- Provided inputs on health economics discussions to Global affiliates.
- Responsible to give health economic inputs into the Global Product Strategic Business Plan

Probation

Bayer Healthcare Co.

London, May 2007 – August 2007

- Dissertation about a Cost-Effectiveness Study of Rivaroxaban integrated in the Global Launch of the Product
- Dissertation was done under the supervision of the Global Project Director from Bayer Healthcare Co.
- The launch of Rivaroxaban involved a cooperation between Bayer and IMS London.

Technical Director

UNIFA/ CPH Pharma, S.A.

Lisbon, January 2003-December 2005

- Regulatory affairs with submissions of products and management of alterations.
- Deputy of Pharmacovigilance having received formation in EMA.
- Scientifically education of Marketing Teams
- Negotiations with Manufacturers regarding the production of CPH products, clients and organizations of pharmaceutical, cosmetic and medical device sectors.
- Co-responsible by the optimal conditions of storage of CPH Pharma and Astra-Zeneca products in Portugal.
- Line management of the storage team constituted by 18 persons.

Education

M.Sc. Epidemiology

Faculty of Medicine of the University of Lisbon, Feb 2012-

This program is regarded as one of the top in this area in Portugal. It includes subjects like Epidemiology, Statistics, Project Planning, Sampling, Health Economics and Clinical Epidemiology and it is supposed to equip with critical epidemiological skills to allow to study the determinants of health and its distribution in the population and to design preventive policies in the healthcare sector.

The main project of the MSc was an, English written, epidemiological study about the effect of pre-anesthetic visit in the pre-surgical anxiety. The dissertation is an, English written, systematic review about cost effectiveness studies in the area of the DPP4 inhibitors and is going to be finished during the year of 2014.

Decision Analytic Modelling for Economic Evaluation - Foundations and Advanced Courses

University of York, March 2013

Lisbon- Executive MBA(not completed)

University Católica/Nova of Lisbon, October 2009- July 2010

M.Sc. Health Economics

University of York, 2006-2007

The MSc Program in Health Economics at the University of York is, due to the world-wide reputation of its Health Economics group, regarded as one of the top in the area. It includes subjects like Health Economics, Applied Microeconomics, Econometrics, Cost-Effectiveness Analyses, Evaluation of Healthcare and Clinical Decision Analysis and it's believed to equip with the critical economic skills to support the concept of health decision based on evidence.

Degree in Pharmaceutical Sciences

Faculty of Pharmacy of the University of Lisbon, 1994- 2001

Computer competencies; language skills

SPSS and Microsoft Office tools.

Speaks:

- Portuguese (native)
- English (fluent)
- Spanish (good reading and speaking skills, basic writing skills)
- French (basic)

Interests, Activities and Publications

Cinema, sports, travelling, reading

Invited Lecturer of the Portuguese Society of Gastroenterology Post-Graduation course of Epidemiology for Gastroenterologists 2014

Mentor of Students of the University of York through the “Alumni Mentoring Scheme” 2014

International Health Economic Association (IHEA) abstracts reviewer for the Dublin Congress of 2014

Presence in ISPOR Congress in Athens in 2008

Co-author of the Poster “Cross-country comparison of International prescribing patterns versus Portugal and potential cost savings” presented in ISPOR Congress in Dublin in 2013

Presence in ISPOR Congress in Amsterdam in 2014

Author of the Poster “The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: A Systematic Review of Cost-Effectiveness Studies” presented in ISPOR Congress in Amsterdam in November 2014

Presence in 4 short-courses of health economics in ISPOR congress: Cost-effectiveness alongside clinical trials, systematic reviews and meta-analysis, transferability of cost-effectiveness data between countries, budget impact modeling.

